Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZBG in Treatment-Naïve Advanced Follicular Lymphoma
NCT07126678Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Open-label, single-arm trial of zanubrutinib in follicular lymphoma (FL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07126678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07126678.